Oak Harbor Wealth Partners LLC Sells 2,134 Shares of DexCom, Inc. (NASDAQ:DXCM)

Oak Harbor Wealth Partners LLC cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 37.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,603 shares of the medical device company’s stock after selling 2,134 shares during the quarter. Oak Harbor Wealth Partners LLC’s holdings in DexCom were worth $280,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc bought a new position in shares of DexCom during the fourth quarter worth approximately $25,000. Private Trust Co. NA increased its holdings in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the period. Larson Financial Group LLC increased its holdings in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares during the period. Heck Capital Advisors LLC bought a new position in shares of DexCom during the fourth quarter worth approximately $38,000. Finally, SBI Securities Co. Ltd. bought a new position in shares of DexCom during the fourth quarter worth approximately $49,000. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,083 shares of company stock valued at $3,309,794 over the last quarter. Insiders own 0.30% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $77.84 on Friday. The firm has a market cap of $30.42 billion, a PE ratio of 54.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The firm’s fifty day moving average is $84.83 and its 200-day moving average is $76.96. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and increased their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Canaccord Genuity Group increased their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Morgan Stanley increased their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Finally, Wells Fargo & Company increased their price target on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.